|
|
||||||||
Institute of Pathophysiology, University of Essen Medical School, 45122 Essen, Germany
| |
ABSTRACT |
|---|
|
|
|---|
Protein kinase C
(PKC
) plays a central role in ischemic preconditioning (IP)
in mice and rabbits, and activated PKC
colocalizes with and
phosphorylates connexin43 (Cx43) in rats and humans. Whether or not
Cx43 contributes to the mechanism(s) of IP in vivo is yet unknown.
Therefore, wild-type (n = 8) and heterozygous Cx43-deficient mice
(n = 8) were subjected to 30 min occlusion and 120 min reperfusion
of the left anterior descending coronary artery. IP was induced by one
cycle of 5 min occlusion and 10 min reperfusion (n = 8/8 mice) before the sustained occlusion. Infarct size was reduced by
IP in wild-type mice [11.3 ± 3.4% vs. 23.7 ± 7.2% of the
left ventricle (LV), P < 0.05] but not in
Cx43-deficient mice (26.0 ± 6.0% vs. 25.1 ± 3.8% of LV).
Also, three cycles of 5 min occlusion and 10 min reperfusion (n = 5) did not induce protection in Cx43-deficient mice (27.6 ± 5.5 % of LV). Thus Cx43 contributes to the protection of IP in mice in vivo.
mouse heart in situ; infarct size; gap junctions
| |
INTRODUCTION |
|---|
|
|
|---|
ISCHEMIC
PRECONDITIONING (IP) by brief episodes of
ischemia-reperfusion protects the myocardium from the damage
induced by a subsequent more prolonged ischemia. Several
triggers and mediators of IP have been identified, whereas the final
end effector is still unknown (15). Protein kinase C
(PKC
) is an established mediator of IP in mice and rabbits, whereas
other PKC isoforms may be more important in other species
(15). PKC
is involved in signaling complexes with at
least 36 proteins (1, 9, 18), among them connexin43 (Cx43)
(10), an integral protein of myocardial gap junctions.
Activated PKC
colocalizes with Cx43 and contributes to
phosphorylation of Cx43 in rats (3) and humans
(2), which might then modulate gap junction transmission characteristics and intercellular communication. Indeed, in isolated mouse hearts, uncoupling of gap junctions using heptanol abolished infarct size reduction by IP (8). The data on the effect
of gap junction uncoupling on infarct size per se are controversial. Pretreatment with the gap junction uncoupler heptanol had no effect on
infarct size in isolated rabbit hearts (6), but heptanol given during early ischemia decreased infarct size in isolated rabbit hearts (16). Also, in pigs in vivo heptanol given
during early reperfusion decreased infarct size (4). Data
on the importance of Cx43 for IP in vivo, however, are lacking. We
therefore studied whether or not Cx43 is involved in the
cardioprotection by IP using heterozygous Cx43-deficient mice.
| |
EXPERIMENTAL PROCEDURES |
|---|
|
|
|---|
The experimental protocols were approved by the bioethics committee of the district of Düsseldorf, Germany. Mice were handled according to the guidelines of the American Physiological Society.
We used the in situ mouse heart model developed by Guo et al. (5). Briefly, male and female C57BL/6J wild-type and heterozygous Cx43-deficient mice (B6.129-Gja1tm1Kdr, JAX mice; Bar Harbor, ME) (12) (weight: 30.5 ± 4.5 g, age: 14-20 wk) were anesthetized with pentobarbital sodium (80 mg/kg ip) and atropine sulfate (0.04 mg/kg ip). Electrocardiogram and rectal temperature were monitored continuously. Temperature was held close to 37°C. After intubation (polyethlene-60 tubing) and with ventilation (oxygen-supplemented room air, 105 breaths/min ZOOVENT Jetsys, Universal Lung Ventilators; Netherfield, UK), a midline thoracotomy and pericardiotomy were performed. With the use of a 9.0-nylon suture, a nontraumatic balloon occluder was attached to the left anterior descending coronary artery 1 mm distal to the tip of the left auricle. Control mice (n = 8/8) underwent 30 min occlusion and 120 min reperfusion. IP was induced by 5 min occlusion and 10 min reperfusion before the sustained occlusion (1×IP, n = 8/8). Five additional Cx43-deficient mice were subjected to three cycles of 5 min occlusion and 10 min reperfusion (3×IP). At the end of the protocol, mice were heparinized, and the hearts were rapidly excised and immersed into ice-cold saline (~4°C). The aorta was cannulated and perfused with Krebs-Henseleit solution, 1% 2,3,5-triphenyltetrazolium chloride, and 10% KCl. Hearts were cut into four to five transverse slices, and infarct size was measured by planimetry and expressed as a percentage of the left ventricle (8).
For Western immunoblotting of Cx43, a primary rabbit anti-Cx43 (Zymed;
San Francisco, CA) and secondary anti-rabbit IgG horseradish peroxidase-conjugated antibody (Cell Signaling; Beverly, MA) were used.
Analysis of the amount of Cx43 was performed in right ventricular tissue (14.4 ± 5.3 mg) by enhanced chemiluminescence and
quantitative two-dimensional densitometry
(wild-type/Cx43+/
, n = 4/3 mice).
Data are means ± SD. Data analysis was performed with Sigma Stat software (Jandel Scientific; San Rafael, CA) by one-way ANOVA. A P value <0.05 was taken to indicate statistical significance.
| |
RESULTS AND DISCUSSION |
|---|
|
|
|---|
Heart rate and temperature were not different among the five
groups throughout the protocol (Table 1).
The heterozygous Cx43-deficient mice had 55.5 ± 9.3% of
wild-type right ventricular Cx43 expression (Fig.
1). Infarct size was reduced by IP in
wild-type mice but not in heterozygous Cx43-deficient mice, not even
when subjected to three IP cycles (Fig.
2).
|
|
|
Heterozygous Cx43-deficient mice have the same phenotype as wild-type mice (7). In the present study, heart rate was comparable between groups, and Cx43-deficient mice also had no electrocardiogram abnormalities. In the present study, 30-min occlusion and 120-min reperfusion resulted in similar infarct sizes in both genotypes. Thus Cx43 deficiency per se does not exaggerate tissue damage under sustained ischemia. In contrast, the infarct-sparing effect of IP was completely abolished in heterozygous Cx43-deficient mice. Apparently 50% of Cx43 is not sufficient to sustain the mechanism(s) of IP.
Our findings are somewhat contrary to prior findings in rat brain cells exposed to ischemia, which close their gap junctions to isolate themselves from surrounding cells (11). If this were true for cardiomyocytes, Cx43 deficiency in our study should have been cardioprotective. There is, however, good evidence that gap junctions are open at some time point during myocardial ischemia. In isolated rat cardiomyocytes and hearts, open gap junctions permit the equilibration of cytosolic concentrations of Na+ and Ca2+, thus contributing to propagation of rigor contracture (13, 14). In isolated mouse hearts, uncoupling of gap junctions using heptanol abolished IP protection, suggesting that an as-yet-unknown "survival" factor may be transmitted via gap junctions during IP (8). Also in the present study in vivo, to the extent that gap junctions remained open, the lack of IP in heterozygous Cx43-deficient mice points to the importance of intercellular communication (17) in the mechanism(s) of IP.
A number of recent investigations revealed that activated PKC
forms
signaling complexes with other proteins, which can be categorized as
structural proteins, signaling proteins (Cx43 among them), and
stress-activated proteins (10). The composition of such
complexes is dynamically altered and causally involved in cardioprotective signaling (10, 19). The recruitment of
Cx43 to the PKC
signaling complex is associated with
posttranslational modification of Cx43 during cardioprotection
(10). Alternatively, disruption of the PKC
-Cx43
signaling complex could act to prevent phosphorylation of some other
unidentified targets associated with the complex. Obviously, a 50%
reduction of functioning PKC
-Cx43 signaling complexes is sufficient
to completely abolish the infarct-sparing effect by IP. We propose Cx43
might be involved in cellular volume regulation, which is considered as
one potential end effector of IP (15).
| |
FOOTNOTES |
|---|
Address for reprint requests and other correspondence: G. Heusch, Institut für Pathophysiologie, Universitätsklinikum Essen, Hufelandstraße 55, 45122 Essen, Germany (E-mail: gerd.heusch{at}uni-essen.de).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
10.1152/ajpheart.00442.2002
Received 23 May 2002; accepted in final form 25 June 2002.
| |
REFERENCES |
|---|
|
|
|---|
1.
Baines, CP,
Zhang J,
Wang GW,
Zheng YT,
Xiu JX,
Cardwell EM,
Bolli R,
and
Ping P.
Mitochondrial PKC
and MAPK form signaling modules in the murine heart.
Circ Res
90:
390-397,
2002
2.
Bowling, N,
Huang X,
Sandusky GE,
Fouts RL,
Mintze K,
Esterman M,
Allen PD,
Maddi R,
McCall E,
and
Vlahos CJ.
Protein kinase C-
and -
modulate connexin-43 phosphorylation in human heart.
J Mol Cell Cardiol
33:
789-798,
2001[Web of Science][Medline].
3.
Doble, BW,
Ping P,
and
Kardami E.
The
subtype of protein kinase C is required for cardiomyocyte connexin-43 phosphorylation.
Circ Res
86:
293-301,
2000
4.
Garcia-Dorado, D,
Inserte J,
Ruiz-Meana M,
Gonzalez MA,
Solares J,
Julia M,
Barrabés JA,
and
Soler-Soler J.
Gap junction uncoupler heptanol prevents cell-to-cell progression of hypercontracture and limits necrosis during myocardial reperfusion.
Circulation
96:
3579-3586,
1997
5.
Guo, Y,
Wu WJ,
Qiu Y,
Tang XL,
Yang Z,
and
Bolli R.
Demonstration of an early and a late phase of ischemic preconditioning in mice.
Am J Physiol Heart Circ Physiol
275:
H1375-H1387,
1998
6.
Gysembergh, A,
Kloner RA,
and
Przyklenk K.
Pretreatment with the gap junction uncoupler heptanol does not limit infarct size in rabbit heart.
Cardiovasc Pathol
10:
13-17,
2001[Web of Science][Medline].
7.
Kirchhoff, S,
Kim JS,
Hagendorff A,
Thönissen E,
Krüger O,
Lamers WH,
and
Willecke K.
Abnormal cardiac conduction and morphogenesis in connexin40 and connexin43 double-deficient mice.
Circ Res
87:
399-405,
2000
8.
Li, G,
Whittaker P,
Yao M,
Kloner RA,
and
Przyklenk K.
The gap junction uncoupler heptanol abrogates infarct size reduction with preconditioning in mouse hearts.
Cardiovasc Pathol
11:
158-165,
2002[Web of Science][Medline].
9.
Ping, P,
Song C,
Zhang J,
Guo Y,
Cao X,
Li RCX,
Wu W,
Vondriska TM,
Pass JM,
Tang XL,
Pierce WM,
and
Bolli R.
Formation of protein kinase C
-Lck signaling modules confers cardioprotection.
J Clin Invest
109:
499-507,
2002[Web of Science][Medline].
10.
Ping, P,
Zhang J,
Pierce WM,
and
Bolli R.
Functional proteomic analysis of protein kinase C
signaling complexes in the normal heart and during cardioprotection.
Circ Res
88:
59-62,
2001
11.
Rawanduzy, A,
Hansen A,
Hansen TW,
and
Nedergaard M.
Effective reduction of infarct volume by gap junction blockade in a rodent model of stroke.
J Neurosurg
87:
916-920,
1997[Web of Science][Medline].
12.
Reaume, AG,
de Sousa PA,
Kulkarni S,
Langille BL,
Zhu D,
Davies TC,
Jeneja SC,
Kidder GM,
and
Rossant J.
Cardiac malformation in neonatal mice lacking connexin43.
Science
267:
1831-1834,
1995
13.
Ruiz-Meana, M,
Garcia-Dorado D,
Hofstaetter B,
Piper HM,
and
Soler-Soler J.
Propagation of cardiomyocyte hypercontracture by passage of Na+ through gap junctions.
Circ Res
85:
280-287,
1999
14.
Ruiz-Meana, M,
Garcia-Dorado D,
Lane S,
Pina P,
Inserte J,
Mirabet M,
and
Soler-Soler J.
Persistence of gap junction communication during myocardial ischemia.
Am J Physiol Heart Circ Physiol
280:
H2563-H2571,
2001
15.
Schulz, R,
Cohen MV,
Behrends M,
Downey JM,
and
Heusch G.
Signal transduction of ischemic preconditioning.
Cardiovasc Res
52:
181-198,
2001
16.
Tanno, M,
Tsuchida A,
Nishino Y,
Matsumoto T,
Genda S,
Sakamoto J,
and
Miura T.
Blockade of gap junction communication during the early period of ischemia protects cardiomyocytes from infarction (Abstract).
Circulation
104:
II-43,
2001.
17.
van Veen, TAB,
van Rijen HVM,
and
Opthof T.
Cardiac gap junction channels: modulation of expression and channel properties.
Cardiovasc Res
51:
217-229,
2001
18.
Vondriska, TM,
Klein JB,
and
Ping P.
Use of functional proteomics to investigate PKC
-mediated cardioprotection: the signaling module hypothesis.
Am J Physiol Heart Circ Physiol
280:
H1434-H1441,
2001
19.
Vondriska, TM,
Zhang J,
Song C,
Tang XL,
Cao X,
Baines CP,
Pass JM,
Wang S,
Bolli R,
and
Ping P.
Protein kinase C
-Src modules direct signal transduction in nitric oxide-induced cardioprotection. Complex formation as a means for cardioprotective signaling.
Circ Res
88:
1306-1313,
2001
This article has been cited by other articles:
![]() |
M. Ruiz-Meana, A. Rodriguez-Sinovas, A. Cabestrero, K. Boengler, G. Heusch, and D. Garcia-Dorado Mitochondrial connexin43 as a new player in the pathophysiology of myocardial ischaemia reperfusion injury Cardiovasc Res, January 5, 2008; (2008) cvm062v2. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Boengler, I. Konietzka, A. Buechert, Y. Heinen, D. Garcia-Dorado, G. Heusch, and R. Schulz Loss of ischemic preconditioning's cardioprotection in aged mouse hearts is associated with reduced gap junctional and mitochondrial levels of connexin 43 Am J Physiol Heart Circ Physiol, April 1, 2007; 292(4): H1764 - H1769. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Eckle, A. Grenz, D. Kohler, A. Redel, M. Falk, B. Rolauffs, H. Osswald, F. Kehl, and H. K. Eltzschig Systematic evaluation of a novel model for cardiac ischemic preconditioning in mice Am J Physiol Heart Circ Physiol, November 1, 2006; 291(5): H2533 - H2540. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Przyklenk, M. Maynard, and P. Whittaker First molecular evidence that inositol trisphosphate signaling contributes to infarct size reduction with preconditioning Am J Physiol Heart Circ Physiol, October 1, 2006; 291(4): H2008 - H2012. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Mullick, Z. Leon, G. Min-Oo, J. Berghout, R. Lo, E. Daniels, and P. Gros Cardiac Failure in C5-Deficient A/J Mice after Candida albicans Infection. Infect. Immun., August 1, 2006; 74(8): 4439 - 4451. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Vetterlein, C. Muhlfeld, C. Cetegen, R. Volkmann, C. Schrader, and G. Hellige Redistribution of connexin43 in regional acute ischemic myocardium: influence of ischemic preconditioning Am J Physiol Heart Circ Physiol, August 1, 2006; 291(2): H813 - H819. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Rodriguez-Sinovas, D. Garcia-Dorado, M. Ruiz-Meana, and J. Soler-Soler Protective effect of gap junction uncouplers given during hypoxia against reoxygenation injury in isolated rat hearts Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H648 - H656. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Miura, Y. Ohnuma, A. Kuno, M. Tanno, Y. Ichikawa, Y. Nakamura, T. Yano, T. Miki, J. Sakamoto, and K. Shimamoto Protective role of gap junctions in preconditioning against myocardial infarction Am J Physiol Heart Circ Physiol, January 1, 2004; 286(1): H214 - H221. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Padilla, D. Garcia-Dorado, A. Rodriguez-Sinovas, M. Ruiz-Meana, J. Inserte, and J. Soler-Soler Protection afforded by ischemic preconditioning is not mediated by effects on cell-to-cell electrical coupling during myocardial ischemia-reperfusion Am J Physiol Heart Circ Physiol, November 1, 2003; 285(5): H1909 - H1916. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. YELLON and J. M. DOWNEY Preconditioning the Myocardium: From Cellular Physiology to Clinical Cardiology Physiol Rev, October 1, 2003; 83(4): 1113 - 1151. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |